Article in Proceedings of the National Academy of Sciences of the United States of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 10 citations in OpenAlex.
Nadire DuruCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201.ORCID 0000-0001-9066-8191
Nisha R PawarCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201.
Erik W MartinCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201.ORCID 0000-0003-3979-2378
Marguerite S BuzzaCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201.
Gregory D ConwayCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201.ORCID 0000-0002-9520-887X
Rena G LapidusMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201.ORCID 0000-0002-4422-743X
Shihui LiuNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.ORCID 0000-0003-3444-1069
Jocelyn ReaderMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201.
Gautam G RaoMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201.
Dana M RoqueMarlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, Baltimore, MD 21201.
Stephen H LepplaNational Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892.ORCID 0000-0001-5233-0501
Toni M AntalisCenter for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, MD 21201.
University of Maryland, Baltimore · USNational Institute of Allergy and Infectious Diseases · US
Funding
Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Jon C.D. Houtman · 2000 to 2026
$70.0M
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI FEYRUZ VIRGILIA RASSOOL · 2008 to 2026
$51.0M
Vaccines and Therapeutics for AnthraxZIAAI000929 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LEPPLA, STEPHEN · 2009 to 2025
$15.9M
Training Grant in Cancer BiologyT32CA154274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Toni M Antalis, CURT I CIVIN · 2011 to 2026
$6.8M
TRAINING PROGRAM IN INTEGRATIVE MEMBRANE BIOLOGYT32GM008181 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI RIZZO, MEGAN A, TRUDEAU, MATTHEW C · 1987 to 2022
$4.9M
UMB Postbaccalaureate Research Education ProgramR25GM113262 · NIGMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M, CAREY, GREGORY B · 2016 to 2025
$3.2M
Mechanisms of anthrax lethal toxin-induced mortality and the novel biological-based targeted therapiesR01AI170574 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Shihui Liu · 2023 to 2026
$2.4M
Developmental therapy for selectively targeting MEK-ERK pathway in cancer cells and tumor stromal compartmentR01CA254938 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI LIU, SHIHUI · 2021 to 2025
$2.2M
Protease activated receptor-2 (PAR-2) signaling and metastatic ovarian cancerR01CA196988 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M · 2017 to 2021
$1.8M
Membrane Serine Protease Activities in Protease Activated Receptor SignalingR01HL118390 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI ANTALIS, TONI M · 2014 to 2017
$1.5M
HHS | National Institutes of Health (NIH) P30CA134274HHS | National Institutes of Health (NIH) T32CA154274HHS | National Institutes of Health (NIH) T32GM008181NCI NIH HHS P30 CA134274NCI NIH HHS R01 CA196988NCI NIH HHS R01 CA254938NCI NIH HHS T32 CA154274NHLBI NIH HHS R01 HL118390NIAID NIH HHS R01 AI170574NIGMS NIH HHS R25 GM113262NIGMS NIH HHS T32 GM008181
6 · The paper itself
Abstract
Treatments for advanced and recurrent ovarian cancer remain a challenge due to a lack of potent, selective, and effective therapeutics. Here, we developed the basis for a transformative anticancer strategy based on anthrax toxin that has been engineered to be selectively activated by the catalytic power of zymogen-activating proteases on the surface of malignant tumor cells to induce cell death. Exposure to the engineered toxin is cytotoxic to ovarian tumor cell lines and ovarian tumor spheroids derived from patient ascites. Preclinical studies demonstrate that toxin treatment induces tumor regression in several in vivo ovarian cancer models, including patient-derived xenografts, without adverse side effects, supportive of progression toward clinical evaluation. These data lay the groundwork for developing therapeutics for treating women with late-stage and recurrent ovarian cancers, utilizing a mechanism distinct from current anticancer therapies.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Selective targeting of metastatic ovarian cancer using an engineered anthrax prodrug activated by membrane-anchored serine proteases. · full record | OpenQuestion